PAXMEDICA INC (PXMD)

Company Profile

PaxMedica Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tarrytown, New York and currently employs 3 full-time employees. The company went IPO on 2022-08-19. PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.

Company Info

PAXMEDICA INC

303 South Broadway, Suite 125

Tarrytown NEW YORK

P: 19149872876

Employees: 3

Website: https://www.paxmedica.com/